Palmitoylethanolamide (PEA) is an endogenous lipid mediator belonging to the N-acyl-ethanolamine family, widely recognized for its multifaceted effects on neuroprotection, chronic pain management, and immune modulation. As a naturally occurring compound, PEA plays a crucial role in maintaining homeostasis under conditions of cellular stress and inflammation. Its pharmacological effects are primarily mediated through peroxisome proliferator-activated receptor-alpha (PPAR-α) activation, alongside indirect modulation of cannabinoid receptors CB1 and CB2, as well as interactions with novel targets such as GPR55 and TRPV1. These molecular mechanisms underpin its broad therapeutic potential, particularly in the management of neuroinflammatory and neurodegenerative disorders, pain syndromes, and immune dysregulation. A major advancement in PEA research has been the development of ultramicronized palmitoylethanolamide (umPEA), which significantly enhances its bioavailability and therapeutic efficacy by facilitating better tissue absorption and interaction with key molecular pathways. Preclinical and clinical studies have demonstrated that umPEA is particularly effective in reducing neuroinflammation, stabilizing mast cells, and enhancing endocannabinoid system activity, making it a promising candidate for integrative approaches in neuropsychiatric and chronic inflammatory diseases. Given its well-established safety profile, umPEA represents an attractive alternative or adjunct to conventional anti-inflammatory and analgesic therapies. This communication provides a comprehensive overview of the mechanisms of action and therapeutic applications of both PEA and umPEA, emphasizing their emerging role in clinical practice and personalized medicine.
The increasing focus on integrative approaches for the management of neuroinflammatory and immune-related disorders has prompted the investigation of natural compounds with potential modulatory effects. Among these, palmitoylethanolamide (PEA), especially in its ultramicronized palmitoylethanolamide (umPEA), is gaining recognition as a promising therapeutic option for these conditions. Based on growing preclinical and clinical evidence, we argue that umPEA deserves greater consideration within therapeutic protocols, especially in neuropsychiatric care and personalized medicine. PEA, an endogenous bioactive lipid mediator belonging to the N-acyl-ethanolamine (NAE) family, has garnered significant attention due to its diverse pharmacological properties. In response to cellular stress or injury, this compound is synthesized on demand within the lipid bilayer and exerts its effects locally within tissues, including the brain. PEA is upregulated in pathological conditions, indicating its role as a protective and homeostatic agent. Its broad spectrum of biological activities includes anti-inflammatory, analgesic, anticonvulsant, antimicrobial, antipyretic, antiepileptic, immunoregulatory, and neuroprotective effects.
PEA is synthesized on demand within the lipid bilayer via a two-step enzymatic process. The initial step involves a calcium- and cAMP-dependent transfer of palmitic acid from phosphatidylcholine to phosphatidylethanolamine, generating N-acylphosphatidylethanolamine (NAPE), which is then hydrolyzed by an NAPE-specific phospholipase D to release PEA. Its degradation is mediated by fatty acid amide hydrolase (FAAH) and a PEA-preferring acid amidase (PAA), both converting PEA into palmitic acid and ethanolamine. Beyond its direct effects, PEA also modulates the endocannabinoid system by inhibiting FAAH, the enzyme responsible for degrading anandamide (AEA). As a result, AEA levels increase, promoting greater activation of cannabinoid receptors CB1 and CB2 and contributing to anti-inflammatory and analgesic actions through the so-called “entourage effect”. PEA has been detected in virtually all mammalian tissues, including the brain. Although the regulation of its endogenous levels is not yet fully understood, several studies indicate that PEA concentrations rise in response to tissue injury and cellular stress. This supports the notion that PEA functions as an intrinsic protective agent, mobilized to restore local homeostasis and counteract inflammation. For instance, in response to cellular damage or tissue injury, macrophages, mast cells, and keratinocytes are known to release PEA as part of the body’s natural response to mitigate inflammation and promote healing. In the brain, PEA has been shown to increase in conditions including neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, as well as multiple sclerosis and traumatic brain injury. PEA also exerts neuroprotective effects, protecting neuronal cells from oxidative damage and neurodegeneration.
The therapeutic potential of PEA is driven by its interactions with several molecular targets. A primary target is PPAR-α, a nuclear receptor involved in regulating lipid metabolism and inflammation. By promoting fatty acid oxidation and reducing pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, PEA helps manage conditions such as metabolic syndrome and cardiovascular diseases, highlighting its role in correcting lipid dysregulation and chronic inflammation.
The increasing prevalence of chronic degenerative diseases is a major global health concern, driven in part by the nutrition transition, a shift in dietary and lifestyle patterns toward the consumption of highly processed foods, sedentary behaviors, and exposure to environmental stressors. These changes have led to widespread metabolic imbalances, chronic inflammation, and an overall decline in health, predisposing individuals to a range of chronic conditions such as metabolic syndrome, cardiovascular diseases, neurodegenerative disorders, gastrointestinal diseases, and autoimmune conditions.
Despite advancements in pharmacological treatments, the toxicity and side effects associated with long-term drug use limit their application in preventive medicine. Therefore, an urgent need is to explore alternative strategies to restore metabolic homeostasis and improve public health outcomes. Nutritional supplementation has emerged as a promising avenue for recreating pre-industrial dietary profiles and mitigating the impact of modern dietary insufficiencies. Ideal supplements should possess anti-inflammatory, antioxidant, immunomodulatory, neuroprotective, and analgesic properties while enhancing cognitive function and overall recovery processes.
Additionally, PEA activates TRPV1, a receptor involved in pain perception and neuroinflammation. This activation leads to desensitization of sensory neurons, resulting in reduced pain. Additionally, PEA stabilizes mast cells, reducing allergic and inflammatory responses, underscoring its potential in treating neuropathic pain and chronic pain syndromes. PEA also interacts with GPR55 and GPR119, two GPCRs involved in lipid metabolism and pain modulation. While the exact mechanisms are still under investigation, these interactions suggest additional pathways through which PEA may exert therapeutic effects, particularly in metabolic and neurodegenerative diseases.
The therapeutic versatility of PEA, particularly in its umPEA, has been demonstrated across a broad spectrum of conditions, including allergic and respiratory disorders, viral infections, chronic pain syndromes, musculoskeletal diseases, psychiatric illnesses, and neurodegenerative disorders. Moreover, umPEA supplementation has been associated with enhanced muscle recovery, improved cognitive performance, mood stabilization, and better sleep regulation. Exogenous administration offers a promising strategy for restoring physiological balance since endogenous PEA levels are often insufficient to counteract the persistent inflammatory stress linked to chronic diseases.
Currently, several PEA-containing formulations are available as nutraceuticals, dietary supplements, or medical foods in various countries; however, the ultra-micronized formulation of PEA alone can cross biological barriers, including the blood–brain barrier, thereby ensuring therapeutically active concentrations. These products are typically administered at a recommended daily dosage of 1200 mg. Notably, PEA’s long-established safety profile, supported by both clinical and preclinical research dating back to the 1950s, further reinforces its potential as a valuable adjunctive therapy for managing chronic health conditions. Considering the growing scientific evidence on the role of PEA in modulating inflammation and pain, this communication aims to summarize its key mechanisms of action and explore its potential clinical applications. Specifically, we will discuss the value of PEA, and particularly umPEA, as a safe and effective therapeutic option for chronic inflammatory conditions, neurodegenerative diseases, and immune system disorders.
umPEA is a specifically engineered formulation of PEA, obtained by subjecting standard PEA to a controlled ultramicronization process. Ultramicronization involves mechanically reducing the particle size of PEA crystals to dimensions typically below 10 μm. This significant reduction in particle size increases the surface area of the compound, thereby markedly improving dissolution rates and facilitating rapid and enhanced absorption through the gastrointestinal mucosa. These pharmacological enhancements directly translate into greater clinical effectiveness, allowing lower effective doses and yielding improved therapeutic outcomes across various inflammatory, neuropathic, and neurodegenerative conditions. Such advantages have been validated by multiple pharmacokinetic studies and clinical trials, reinforcing the therapeutic superiority of umPEA in clinical practice.
Standard formulations of PEA are characterized by limited oral bioavailability and suboptimal tissue distribution, restricting their therapeutic effectiveness. umPEA, obtained through an advanced ultramicronization process that reduces particle size to the micrometer scale, significantly enhances PEA’s pharmacokinetic profile. The ultramicronization markedly increases gastrointestinal absorption, leading to higher systemic
